BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29378725)

  • 1. Variability of PD-L1 expression in mastocytosis.
    Hatch EW; Geeze MB; Martin C; Salama ME; Hartmann K; Eisenwort G; Blatt K; Valent P; Gotlib J; Lee JH; Chen L; Ward HH; Lidke DS; George TI
    Blood Adv; 2018 Feb; 2(3):189-199. PubMed ID: 29378725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis.
    Aberer E; Sperr WR; Bretterklieber A; Avian A; Hadzijusufovic E; Kluin-Nelemans HC; Oude Elberink H; van Anrooij B; Niedoszytko M; Lange M; Górska A; Elena C; Brazzelli V; Belloni Fortina A; Caroppo F; Hartmann K; Illerhaus A; Reiter A; Jawhar M; Bonadonna P; Zanotti R; Triggiani M; Parente R; Gotlib J; Doubek M; von Bubnoff N; Fuchs D; Sabato V; Brockow K; Jäkel N; Panse J; Valent P
    J Invest Dermatol; 2021 Jul; 141(7):1719-1727. PubMed ID: 33581142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review.
    Leguit R; Hebeda K; Kremer M; van der Walt J; Gianelli U; Tzankov A; Orazi A
    Pathobiology; 2020; 87(1):2-19. PubMed ID: 31802761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression in Mastocytosis.
    Williams M; Lidke DS; Hartmann K; George TI
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31086024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
    Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
    Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2010; 77(4):169-80. PubMed ID: 20616612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
    Valent P; Sperr WR; Schwartz LB; Horny HP
    J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mastocytosis and eosinophilic leukemia: diagnostics and classification].
    Sotlar K; Valent P; Horny HP
    Pathologe; 2012 Nov; 33(6):539-52. PubMed ID: 23085697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients.
    Degboé Y; Severino-Freire M; Couture G; Apoil PA; Gaudenzio N; Hermine O; Ruyssen-Witrand A; Paul C; Laroche M; Constantin A; Livideanu CB
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1306-1312. PubMed ID: 38423295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms.
    Valent P; Sotlar K; Horny HP
    Leuk Lymphoma; 2011 May; 52(5):740-4. PubMed ID: 21261503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
    Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
    Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
    Álvarez-Twose I; Jara-Acevedo M; Morgado JM; García-Montero A; Sánchez-Muñoz L; Teodósio C; Matito A; Mayado A; Caldas C; Mollejo M; Orfao A; Escribano L
    J Allergy Clin Immunol; 2016 Jan; 137(1):168-178.e1. PubMed ID: 26100086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
    Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
    Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mastocytosis, classification, biological diagnosis and therapy].
    Arock M
    Ann Biol Clin (Paris); 2004; 62(6):657-69. PubMed ID: 15563424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints.
    Hidalgo-López JE; Kanagal-Shamanna R; Quesada AE; Thakral B; Hu Z; Mitsuhashi T; Yabe M; Garcia-Manero G; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S16-S25. PubMed ID: 28760297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
    Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
    J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment.
    Azaña JM; Torrelo A; Matito A
    Actas Dermosifiliogr; 2016; 107(1):15-22. PubMed ID: 26525106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.